Large deals frequent in the ADC space: Chinese innovative drugmakers' R&D capabilities are gaining recognition

The reporter noted that since the beginning of this year, several Chinese innovative pharmaceutical companies, including Suzhou MedLink Therapeutics, Jiangsu Alphamab Biopharmaceuticals, and Duality Biotherapeutics, have successively reached ADC out-licensing deals. Industry insiders believe that with the continuous development of ADC technology, the R&D capabilities of Chinese innovative pharmaceutical companies are gradually gaining recognition in the international market, and multinational pharmaceutical companies' interest in Chinese ADC assets is extending from single products to multiple R&D projects and technology platforms.